Ultrafiltration Versus IV Diuretics in Worsening Heart Failure

ID#: NCT05318105

Age: 18 years - 66+

Gender: All

Healthy Subjects: No

Study Phase: N/A

Recruitment Status: Recruiting

Start Date: June 28, 2022

End Date: December 30, 2024

Contact Information:
Megan Cotts
952-345-4217
Summary: The REVERSE-HF study is a randomized controlled trial to evaluate clinical outcomes of adjustable ultrafiltration with the Aquadex System as compared to adjustable IV loop diuretics in patients with worsening heart failure (HF) and fluid overload.
Eligibility:

Inclusion Criteria:

- 18 years or older

- Man, or non-pregnant woman

- Admitted to the hospital with a diagnosis of acute decompensated heart failure

- On regularly prescribed oral loop diuretics, Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors or a Mineralcorticoid Receptor Antagonists (MRA) prior to admission

- Fluid overload manifested by at least three clinical indications (e.g., edema, an excess of at least 10 pounds of fluid, etc.)

- Provide written informed consent

Exclusion Criteria:

- New diagnosis of heart failure

- Acute coronary syndromes

- Creatinine ≥ 3.0 mg/dl or planned renal replacement therapies at the time of enrollment

- Contraindications to systemic anticoagulation

- Severe concomitant disease expected to prolong hospitalization or cause death in less than 90 days

- Sepsis or ongoing systemic infection

- Active myocarditis

- Constrictive pericarditis or restrictive cardiomyopathy

- Severe aortic stenosis

- Any condition in the opinion of the investigator that would prevent the patient from follow-up/survival
Find a Clinical Trial